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Extended Report 
The autoimmune-associated genetic variant PTPN22 R620W enhances 
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individuals 
Rachel Bayley1, Kerry A Kite1, Helen M McGettrick1, Jacqueline P Smith2, George D 
Kitas2, Christopher D Buckley1, Stephen P Young1.  
1. Rheumatology Research Group, Centre for Translational Inflammation Research, College 
of Medical and Dental Sciences, School of Immunity and Infection, University of Birmingham, 
Birmingham, B15 2TT, United Kingdom. 
2. Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Russell’s Hall 
Hospital, Dudley, West Midlands, DY1 2HQ, United Kingdom. 
  
Bayley et al PTPN22 R620W enhances neutrophil activation and function 1 
 
Abstract 
Objectives: A genetic variant of the leukocyte phosphatase PTPN22 (R620W) is strongly 
associated with autoimmune diseases including rheumatoid arthritis (RA). Functional studies 
on the variant have focussed on lymphocytes, but it is most highly expressed in neutrophils. 
We have investigated the effects of the variant on neutrophil function in health and in 
patients with RA. 
Methods: Healthy individuals and RA patients were genotyped for PTPN22 (R620W) and 
neutrophils isolated from peripheral blood. Neutrophil adhesion and migration across 
inflamed endothelium were measured. Calcium (Ca2+) release and reactive oxygen species 
(ROS) production in response to fMLP stimulation were also assessed. 
Results: Expression of R620W enhanced neutrophil migration through cytokine activated 
endothelium (non-R620W=24%, R620W=45% migrating cells, p<0.001). Following fMLP 
stimulation, neutrophils that were heterozygous and homozygous for R620W released 
significantly more Ca2+ when compared to non-R620W neutrophils, both in healthy 
individuals and RA patients. fMLP stimulation, after TNF-α priming, provoked  more ROS 
from neutrophils heterozygous for R620W in RA patients (non-R620W vs. R620W = ~1.75-
fold increase) and healthy individuals (non-R620W vs. R620W = 4-fold increase) and this 
increase was statistically significant in healthy individuals (p<0.001) but not in RA patients 
(p<0.25).  
Conclusions: Expression of PTPN22 (R620W) enhanced neutrophil effector functions in 
health and RA, with migration, Ca2+ release and production of ROS increased. Neutrophils 
are found in large numbers in the RA joint and this hyperactivity of R620W cells may directly 
contribute to the joint damage, as well as to the initiation and perpetuation of the chronic 
immune mediated inflammatory processes driving the disease.  
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1. Introduction 
The aetiology of rheumatoid arthritis (RA) is complex but a strong contribution is made by 
polymorphisms in a number of genes, many of which are involved in the regulation of the 
immune response [1]. One such gene is PTPN22 in which a single nucleotide polymorphism 
(SNP) known as R620W, is a prominent risk factor for RA and other autoimmune diseases 
[2]. The consequences of R620W expression have been widely studied in lymphocytes [3-5] 
where the polymorphism alters signalling through the B and T cell receptors. Thus R620W 
may contribute to the survival of a broader repertoire of lymphocytes, some of which may be 
autoreactive [6 7]. The PTPN22 gene has also been suggested to control other lymphocyte 
functions since in its absence in mice, regulatory T cells are increased [8] and their adhesion 
and function are enhanced [9].  
The protein product of the PTPN22 gene is a protein tyrosine phosphatase (Lyp) whose role 
is to counter the effect of tyrosine kinases and regulate signalling pathways by removing 
phosphorylated tyrosine residues from proteins [10]. To date, many of the studies on Lyp 
have been conducted in lymphocytes. However, Lyp is most highly expressed by neutrophils 
[11] where little is currently known about its function. Altered levels of tyrosine 
phosphorylation have been observed in neutrophils isolated from RA patients [12] and such 
cells exhibit resistance to cell death and enhanced effector functions [13]. Furthermore, 
circulating neutrophils isolated from RA patients have been shown to release more calcium 
(Ca2+) in response to stimulation when compared to individuals with non-rheumatic joint 
conditions [14]. While the genotype of the patients in these studies was not reported, these 
data suggest that abnormal neutrophil signalling and function is a specific feature of RA 
neutrophils.  
Quantitatively neutrophils are a major component of the joint infiltrate since up to 90% of 
leukocytes in the RA joint are neutrophils [15]. This suggests they make a significant 
contribution to the inflammatory processes driving joint destruction and in some animal 
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models of arthritis initiation of disease is completely prevented in the absence of neutrophils 
[16]. Many of the mechanisms used by neutrophils to combat infection also cause significant 
collateral tissue damage when neutrophil activation is enhanced or occurs inappropriately. 
For example, the activation-dependent release of proteases and reactive oxygen species 
(ROS) produce significant damage to joint components including lipids and proteins [17 18]. 
The trigger for aberrant neutrophil activation is not clear, but results from changes in 
neutrophil intracellular signalling. In the context of neutrophil intracellular signalling, cytosolic 
Ca2+ increase and release are important mediators of other neutrophil functions such as 
NADPH oxidase activation and adhesion to endothelium. Additionally Ca2+ signalling 
processes are highly regulated by a number of proteins, one of which could be Lyp. Given 
the fact Lyp is abundantly expressed in neutrophils, we investigated the effects of the 
genetic Lyp variant R620W on neutrophil function, to determine whether this genetic variant 
contributes to the altered activation and function of neutrophils in RA. 
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2. Materials and Methods 
All reagents were purchased from Sigma Aldrich (United Kingdom), unless otherwise stated. 
2.1 Experimental procedures 
2.1.1 Subjects 
Patients with RA (508) were recruited from outpatient clinics at University Hospital 
Birmingham NHS Foundation Trust and Russell’s Hall Hospital (Dudley), alongside healthy 
volunteers (107).  All samples were obtained with informed consent and with approval from 
the Edgbaston Research Ethics Committee (12/WM/0077). All RA patients satisfied the 1987 
American College of Rheumatology (ACR) criteria for RA.  
2.1.2 Genotyping 
PB was collected in vacutainers containing EDTA. DNA was extracted from whole blood 
using the QuickGene 810 system (Fujifilm, Japan), as described previously [19]. A Roche 
LightCycler 480 II system (Roche Diagnostics Ltd. UK) identified the single nucleotide 
polymorphism in PTPN22 (rs2476601) by real-time PCR and melting curve analysis using 
primers and probes used previously [20]  
 
2.1.3 Isolation of neutrophils 
PB was obtained in vacutainers containing EDTA. 2% dextran was added (1ml/6ml of blood) 
and the blood left to settle for 30 minutes to separate red blood cells from the buffy coat. 
Percoll gradients (GE Healthcare, UK) were set up by adding 5ml of 56% Percoll to a 15ml 
tube, and a Pasteur pipette was used to add 2.5ml of 80% Percoll underneath. The buffy 
coat was added to Percoll gradients and centrifuged at 190xgav for 25 minutes with no brake. 
The neutrophil layer was removed from the gradient using a Pasteur pipette. Cells were 
washed twice and resuspended at 1.0x106/ml in pre-warmed RPMI 1640 medium 
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supplemented with 10% heat inactivated foetal calf serum (HIFCS) and 1% glutamine 
penicillin streptomycin (GPS) (complete culture medium), before use in experiments. The 
average purity and viability of neutrophils isolated using this method was 96% and 95% 
respectively.  
2.1.4 Adhesion and migration  
Adhesion and transmigration were assessed by direct microscopic observation as previously 
described [21 22]. Briefly, human umbilical endothelial cells (HUVEC) were isolated from 
umbilical cords and cultured.  Tumour necrosis factor-alpha (TNF-α; 0.05 and 5ng/ml; R&D 
Systems, Abingdon, UK) was added to confluent monolayers for 4 hours before the 
adhesion assay. After washing the HUVEC, neutrophils (1x106/ml in M199BSA) were added 
for 6 minutes and then non-adherent neutrophils were removed. Digitised images of the 
endothelial surface were made using phase contrast microscopy at 37oC at 2 and 9 minutes 
from the end of the settling period and analysed offline using Image-Pro Plus software 
(DataCell Ltd, Finchampstead, UK) as previously described [21].  Adhesion was determined 
as the percentage of neutrophils that adhered by counting all adherent cells per image, then 
calculating the number of cells per well and dividing this number by the total number of 
neutrophils added. Transmigration was calculated as a percentage of the adherent cells that 
appeared phase dark (i.e. underneath the endothelial monolayer). Migration velocities 
(µm/minute) of phase-dark neutrophils underneath the HUVEC were determined the average 
distance moved by the centre of the cell per minute.  
2.1.5 Calcium signalling 
Neutrophils (2.0x106/ml in RPMI 1640) were incubated with 1µM Indo-1 AM ester 
(Invitrogen, USA) for 40 minutes at 37°C, before washing twice in Ca2+ containing HBSS at 
400×gav for 6 minutes. Cells (1.5x106) were placed at 37°C for 10 minutes prior to stimulation 
with 50µM fMLP. Samples were placed in a LS50B spectrofluorimeter (Perkin Elmer, UK) 
and maintained in suspension at 37°C using a magnetic stirrer. Data were collected using FL 
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Winlab Version 2.1 software with a dual-emission experimental protocol for Indo-1 AM 
loaded cells.  
2.1.6 Reactive oxygen species production 
Neutrophils (1.0x106/ml in RPMI 1640) were primed with 5ng/ml TNF-α (R&D Systems, 
Abingdon, UK) for 15 minutes at 37°C and then treated with 10µM dihydrorhodamine (DHR) 
for 5 minutes at 37°C. Samples were stimulated with 1µM fMLP for 5 minutes at 37°C, 
washed in ice-cold PBS with centrifugation at 400×gav for 6 minutes and fixed with 2% 
paraformaldehyde in PBS overnight at 4°C. Fixed cells were washed as before, 
resuspended in PBS and ROS production determined by DHR fluorescence detected using 
a CyAn ADP flow cytometer (Beckman Coulter, UK). 
 
2.1.7 Statistics 
Data shown are mean ±SEM. Mann-Whitney U was used for comparison of groups for 
continuous variables, and Fisher’s exact test with a two-tailed p value for the comparison of 
categorical variables. For paired data, Wilcoxon matched-pairs signed rank tests were 
performed. For data comparing more than three groups, analysis was carried out using a 
two-way ANOVA followed by Bonferonni post-test. P values of <0.05 were considered to be 
statistically significant.  
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3. Results 
To allow us to test the hypothesis that expression of PTPN22 R620W alters neutrophil 
function, a large cohort of healthy individuals and RA patients were recruited and genotyped 
for the R620W SNP. The R620W variant was found to be highly expressed in both of the 
populations assessed (Table 1). The frequency of heterozygotes (AG) among the RA 
population was slightly decreased when compared to previous work [20] (23% vs. 30%); 
however the frequency of homozygotes (AA) was the same (2%). Given the paucity of 
homozygotes we felt it was most appropriate to focus functional investigations on the cells 
heterozygous (AG) for the variant allele. To do this neutrophils were isolated from healthy 
individuals (n=16) and RA patients (n=24) closely matched for age and sex. Importantly, 
there were no significant differences in patient demographics such as disease duration, drug 
treatments or levels of inflammation, when groups were compared according to PTPN22 
genotype (Table 2).  
PTPN22 R620W increases neutrophil migration across inflamed endothelium  
Initially we were interested to determine whether R620W altered the ability of neutrophils to 
be recruited to sites of inflammation. To address this we observed the behaviour (adhesion 
and migration) of neutrophils isolated from healthy individuals control (GG) and 
heterozygous (AG) for R620W on endothelial cells (EC) stimulated with TNF-α, as previously 
described [22]. Neutrophil adhesion increased in a TNF-α dose dependent manner, which 
was not affected by the PTPN22 genotype (Figure 1A). We observed low levels of migration 
on resting EC and those stimulated with low dose (0.05ng/ml) TNF-α for both GG and AG 
expressing neutrophils (Figure 1B).  Significantly more AG neutrophils transmigrated through 
EC treated with high dose TNF-α (5ng/ml) at 2 minutes when compared to neutrophils 
isolated from GG individuals (GG=24±4% and AG=44±7% neutrophils migrated, defined as 
phase dark cells; p<0.001, Figure 1B-D). These differences were lost at 9 minutes, with 
similar levels of migration observed at this later time point (GG=38±5% and AG=43±9% 
neutrophils migrated, defined as phase dark cells). These data suggest that AG neutrophils 
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are able to migrate through inflamed endothelium more rapidly when compared to their GG 
counterparts. However, once the cells were underneath the endothelium, neutrophils 
migrated at similar velocities regardless of PTPN22 genotype (GG=8.1±1.1µm/minute and 
AG=7.9±0.8µm/minute).  
PTPN22 R620W increases Ca2+ release by neutrophils in response to fMLP stimulation 
To assess the effect of R620W on overall signalling through surface receptors, N-formyl-
Met-Leu-Phe (fMLP) was added to mimic the presence of formylated peptides derived from 
bacteria which would be present during an infection. Formyl peptide receptor (FPR) 
engagement releases Ca2+ [23], and thus this was measured to give an indication of the 
overall signal induced by FPR activation. Neutrophils isolated from healthy individuals 
heterozygous (AG) and homozygous (AA) for R620W released significantly more Ca2+ in 
response to fMLP when compared to age and sex matched individuals without R620W 
(GG=0.24±0.02 I1R, AG=0.28±0.02 I1R and AA=0.43 I1R, P<0.05, Figure 2 A+C). Similar 
elevated Ca2+ release were also observed in RA patients with the R620W variant (Figure 
2B+C). In fact, Ca2+ release was significantly augmented in neutrophils from RA patients 
when compared to healthy individuals, in a genotype dependent manner: GG<AG<AA 
(GG=0.39±0.04 I1R, AG=0.44±0.02 I1R and AA=0.56 I1R, Figure 2 B+C).  
PTPN22 R620W increases reactive oxygen species production by neutrophils 
following priming with TNF-α 
Given that R620W was shown to increase Ca2+ release, we examined whether other Ca2+ 
dependent functions would also be affected. In order to investigate this, the ability of 
neutrophils to produce ROS in response to TNF-α priming and fMLP stimulation were tested. 
Unstimulated neutrophils from healthy subjects with GG or AG R620W genotype produced 
very little ROS at the basal level (GG=69±13, AG=155±66, n=8, Figure 3 A+B).  Although 
ROS production was increased with priming, no differences were observed between the GG 
and AG genotypes (TNF-α: GG=110±31 vs. AG=274±131, or fMLP: GG=86±18, 
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AG=200±95, n=8).  In response to priming with TNF-α and then fMLP, AG neutrophils 
produced 4-fold more ROS when compared to age, gender-matched GG neutrophils (Figure 
3C). Neutrophils from RA patients produced little ROS at baseline (GG=173±54, AG=87±28, 
n=4, Figure 4). Similar to the healthy individuals, ROS production was significantly elevated 
following treatment with TNF-α and then fMLP, with AG neutrophils producing ~1.75 fold 
more than GG neutrophils (Figure 4). 
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4. Discussion 
The importance of neutrophils in the pathogenesis of RA is becoming increasingly 
recognised [13] and in some animal models of arthritis their absence completely prevents 
the initiation of disease [16]  Increased oxidised lipids and proteins are present in RA joints, 
which may result from enhanced neutrophil activity [17 18]. In particular, release of 
proteases and ROS have been implicated in joint damage via direct oxidation of joint 
components or oxidation of immune cell surface proteins, leading to impaired suppressor cell 
activity and defective immunoregulation [24]. In this study, we investigated a genetic variant 
(R620W) associated with increased risk of RA, to determine if this contributed to altered 
neutrophil function. We have found that expression of R620W enhances the function of 
neutrophils from healthy donors, as characterised by increased trans-endothelial migration, 
increased Ca2+ release, and increased production of ROS. The results with cells for RA 
patients were less clear since, although there was strong trend for enhanced responses in 
R620W neutrophils, this did not reach statistical significance. The greater variability in RA 
patient neutrophil responses may be a consequence of the complex nature and 
heterogeneity of the disease, and such factors as age and smoking. Given that R620W is 
only 1 of the 101 identified RA risk loci [25], patients are likely to express a number of these 
which may also influence the cellular response. In our RA cohort there were some smokers 
which leads to depletion of the antioxidant glutathione [26] and we have shown that the PTP 
activity of Lyp is susceptible to oxidation [27]. We have also shown that, in CD4 T cells from 
the elderly, the PTP CD45 is oxidatively inactivated [28] and so it may well be that the 
oxidation of neutrophil Lyp as a result of smoking or ageing may have confounded our 
results with the RA neutrophils. However, perhaps the greatest potential source of variability 
in the patients would be the drugs they were taking. Neutrophil function is particularly 
influenced by a broad range of therapeutics including glucocorticoids [29], non-steroidals 
[30] and disease modifying drugs [31] and so eliminating all drug effects in these cells from 
these patients with established disease would be ethically impossible.  
Bayley et al PTPN22 R620W enhances neutrophil activation and function 12 
 
Nevertheless the results overall indicate that Lyp plays an important role in the activation 
and responses of neutrophils. The role of Lyp in T cell receptor (TCR) signalling is better 
characterised, where it acts as a negative regulator mainly via dephosphorylating activating 
tyrosine residues of Src family kinases [32]. Neutrophils express a number of PTPs including 
CD45, CD148 and Lyp [11 32 33]. CD45 and CD148 have been reported to regulate 
neutrophil migration [34], whereas a role for Lyp has not yet been identified. T cells 
expressing R620W release less Ca2+ when activated by CD3 stimulation [5], suggesting 
R620W results in hypo-responsive T cells. We have found the opposite in neutrophils, since 
R620W cells were hyper-responsive to stimulation (Figure 2). These contrasting 
observations suggest the effects of R620W differ depending upon the leukocyte subset, and 
highlights the importance of studying innate and adaptive immune cells in parallel.  
The signalling pathways mediating TNF-α priming of neutrophils are not well known, 
however it could be that Lyp is a regulator of these events. TNF-α has been shown to 
increase intracellular Ca2+ in neutrophils, which is associated with increased co-localisation 
of gp91PHOX, a component of the NADPH oxidase enzyme necessary for ROS production 
[35]. It has been proposed that TNF-α moves the cytosolic sub units (p40PHOX p47PHOX, and 
p67PHOX) of the NADPH oxidase closer to the cell membrane prior to stimulation [36]. High 
levels of TNF-α are present in RA joints, and neutrophils from these sites display increased 
p47PHOX phosphorylation and ROS production [37], highlighting increased priming and 
activity of neutrophils. There are a number of phosphorylation sites present in the structure 
of these subunits, which regulate their location and activation status [38-40]. To date, only 
serine and threonine phosphorylation sites have been documented in neutrophils, but a 
study in ECs has shown that p47PHOX can be subject to tyrosine phosphorylation [40]. 
Therefore, it is possible that Lyp could dephosphorylate p47PHOX at this site, and a change in 
Lyp function could alter activity of the NADPH oxidase.  
Ca2+ signalling is regulated by a number of proteins, including Vav, a guanine exchange 
factor (GEF) which acts as an adaptor molecule [41]. Substrate trapping experiments using 
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T cells found that Vav is a substrate of Lyp [42], which may also be the case in neutrophils. 
Vav is also a mediator of β2 integrin-dependent functions including migration [43], 
suggesting changes to Vav phosphorylation could mediate changes in neutrophil function 
induced by R620W. Another potential target for Lyp is phospholipase C (PLC) gamma2, 
important for Fc-receptor and integrin-mediated neutrophil functions [44]. PLC gamma2 is 
activated by phosphorylation downstream of Src-family kinases [44] and Lyp could be 
involved in dephosphorylation of PLC gamma2 to reduce neutrophil activation. Lyp is known 
to target Src-family kinases upstream of PLC gamma1 in T cells [32], which may also be 
similar in neutrophils. Signalling via PLC gamma2 in neutrophils could be of importance in 
RA, as mice lacking PLC gamma2 are protected from the development of arthritis [44].  
Our results show that the presence of R620W has no effect on neutrophil adhesion, but 
results in more rapid transendothelial migration (Figure 1), which is dependent upon ligation 
of ICAM-1 by β2 integrin’s, and triggered by an increase in intracellular Ca2+ [45]. These 
events mediate activation of RHO GTPase and p38 MAPK, which contract the EC, allowing 
neutrophils to migrate [46]. Lyp could regulate these signalling proteins similarly to CD45 
and CD148, which have been shown to regulate PI3K, pERK and Src-family kinases needed 
for migratory responses [34].  
In conclusion, our studies suggest that neutrophils expressing R620W are more intrinsically 
active and more susceptible to priming by TNF-α. Given the success of RA treatments which 
target TNF-α, our work suggests an additional mechanism by which anti-TNF treatment is 
effective is by reducing neutrophil priming and activation in patients with this genetic variant. 
This suggests that stratification of patients by PTPN22 genotype could be beneficial, and 
may help to choose the most appropriate treatment for patients positive for this genetic 
mutation. In particular, this work identifies a genetic mechanism by which over-activation of 
neutrophils could contribute to increased ROS release and subsequent damage in RA joints. 
Lastly, this study highlights that the effects of R620W are not restricted to lymphocytes, 
where previous studies have mainly been focussed. 
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Figure legends 
Figure 1 Heterozygosity for PTPN22 R620W increased neutrophil migration across inflamed 
endothelium. HUVEC were treated in the presence or absence of TNF-α (0, 0.05, 5ng/ml) for 4 
hours. Neutrophils were isolated from healthy individuals control (GG) and heterozygous (AG) for 
PTPN22 R620W and allowed to settle on the HUVEC monolayer for 6 minutes, after which non-
adherent cells were removed by washing and neutrophil behaviour was analysed by phase contrast 
microscopy. (A) Neutrophil adhesion assessed at 2 minutes expressed as a percentage of total cells 
added. ANOVA shows a significant effect of cytokine treatment, but not PTPN22 genotype, on 
neutrophil adhesion, P<0.0001. (B) Neutrophil transmigration was assessed at 2 and 9 minutes and 
expressed as a percentage of adherent cells that had migrated. Figure shows the percentage of 
neutrophils transmigrated after 2 minutes. ANOVA shows a significant effect of cytokine treatment 
(P<0.0001) and PTPN22 genotype (P<0.05) on neutrophil transendothelial migration. Representative 
micrographs of the behaviour of neutrophils isolated from (C) GG or (D) AG individuals on HUVEC 
treated with 5ng/ml TNF. Round phase bright cells are defined as those cells adherent to the surface 
of the endothelium. Dark, distorted phase dark cells are defined as cells that have migrated and are 
underneath the endothelium. Data are mean ± SEM from 6 (GG) and 7 (AG) independent 
experiments. *** = P<0.001 by Bonferonni post-test compared with control (GG) neutrophils.  
Figure 2 Heterozygosity and homozygosity for PTPN22 R620W increases calcium release by 
neutrophils. Neutrophils were isolated from healthy individuals and rheumatoid arthritis patients 
control (GG), heterozygous (AG) and homozygous (AA) for PTPN22 R620W. Cells were washed and 
loaded with the Indo-1 AM ester. Cells were washed again in HBSS and transferred to an acrylic 
cuvette. After a baseline was established, 50µM fMLP was added. (A) One representative measure of 
experiments using neutrophils isolated from healthy individuals, GG (solid line), AG (dashed line) and 
AA (dotted line). (B) One representative measure of experiments using neutrophils isolated from 
rheumatoid arthritis patients, GG (solid line), AG (dashed line) and AA (dotted line). (C) Mean peak 
rise in Indo-1 AM ratio after stimulation of neutrophils isolated from healthy individuals (HI) and 
rheumatoid arthritis patients (RA). Results show the mean (±SEM) of six experiments using healthy 
individuals (GG and AG) and seven experiments using rheumatoid arthritis patients (GG and AG). * 
P<0.05 Wilcoxon matched-pairs signed rank test compared with control (GG) neutrophils. 
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Figure 3 Heterozygosity for PTPN22 R620W enhances the production of reactive oxygen 
species by neutrophils isolated from healthy individuals following priming with TNF-α. 
Neutrophils were isolated from age and sex matched healthy individuals control (GG) and 
heterozygous (AG) for PTPN22 R620W. Neutrophils were primed with TNF-α for 15 minutes at 37°C. 
Dihydrorhodamine (DHR) was added to cells for 5 minutes at 37°C and cells were then stimulated 
with 1μM fMLP for 5 minutes at 37°C. Cells were washed in ice-cold PBS and fixed using 2% 
paraformaldehyde overnight at 4°C. Reactive oxygen species production was assessed by measuring 
DHR fluorescence using flow cytometry. (A) One representative experiment using control neutrophils 
(non-shaded) and heterozygous neutrophils (shaded). The numbers shown in the histogram plots 
refer to the mean fluorescence intensity of DHR measured when control neutrophils (black) and 
heterozygous neutrophils (grey) were assessed by flow cytometry. (B) Average DHR fluorescence in 
unstimulated (black bars), TNF-α primed (white bars), fMLP stimulated (checked bars), and primed 
and stimulated neutrophils (striped bars). (C) Percentage increase in reactive oxygen species 
production by neutrophils primed with TNF-α and stimulated with fMLP, when compared to 
unstimulated neutrophils. Results are expressed as a percentage of control (GG) neutrophils of an 
age and sex matched individual. Results show the mean (±SEM) of eight separate experiments. ** 
P<0.001 Wilcoxon matched-pairs signed rank test compared with control (GG) neutrophils. 
 
Figure 4 Heterozygosity for PTPN22 R620W enhances the production of reactive oxygen 
species by neutrophils isolated from rheumatoid arthritis patients following priming with TNF-
α. Neutrophils were isolated from rheumatoid arthritis patients, control (GG) and heterozygous (AG) 
for PTPN22 R620W. Neutrophils were primed with TNF-α for 15 minutes at 37°C. Dihydrorhodamine 
(DHR) was added to cells for 5 minutes at 37°C and cells were then stimulated with 1μM fMLP for 5 
minutes at 37°C. Cells were washed in ice-cold PBS and fixed using 2% paraformaldehyde overnight 
at 4°C. Reactive oxygen species production was assessed by measuring DHR fluorescence using 
flow cytometry. (A) One representative experiment using control neutrophils (non-shaded) and 
heterozygous neutrophils (shaded). The numbers shown in the histogram plots refer to the mean 
fluorescence intensity of DHR measured when control neutrophils (black) and heterozygous 
neutrophils (grey) were assessed by flow cytometry.  (B) Average DHR fluorescence in unstimulated 
(black bars), TNF-α primed (white bars), fMLP stimulated (checked bars), and primed and stimulated 
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neutrophils (striped bars). (C) Percentage increase in reactive oxygen species production by 
neutrophils primed with TNF-α and stimulated with fMLP, when compared to unstimulated neutrophils. 
Results show the mean (±SEM) of four separate experiments.  
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Table 1 – Frequency of PTPN22 R620W in the cohort of healthy  subjects, disease control subjects 
and rheumatoid arthritis patients  
PTPN22 
R620W 
genotype 
Healthy 
individu
als  
(n=107) 
Rheumatoid 
arthritis 
patients 
(n=380) 
Rheumatoid 
arthritis 
patients 
(n=397)* 
Odds ratio 
for genotype  
(95% CI)  
HI vs. RA 
p 
value 
Control  
(GG) 
79%  
(n=85) 
75% 
(n=284) 
68% 
(n=272) 
- - 
Heterozygote 
(AG) 
20%  
(n=21) 
23%  
(n=87) 
30% 
(n=119) 
1.31  
(0.811-1.882) 
0.372 
Homozygote 
(AA) 
1%  
(n=1) 
2%  
(n=9) 
2% 
(n=6) 
2.11  
(0.187-23.73) 
0.615 
 
* Genotype frequency of PTPN22 R620W from Toms et al 2011 for comparative purposes [20]. 
Differences in genotype frequency between healthy individuals and rheumatoid arthritis patients were 
analysed using Fisher’s exact test with a two-tailed p value with additional calculation of odds ratio. 
There were no significant differences in genotype frequency when comparing healthy individuals and 
rheumatoid arthritis patients. HI; healthy individuals, RA; rheumatoid arthritis.  
 
Table 2 – Demographic data of the study participants used for in vitro neutrophil functional studies 
 
 Healthy individuals  
(n=16) 
Rheumatoid arthritis patients  
(n=24) 
PTPN22 
R620W 
genotype  
GG 
(n=8) 
AG  
(n=8) 
p 
 value 
GG 
(n=12) 
AG 
(n=12) 
p  
value 
Sex, female n 
(%) 
5 (63) 5 (63) 1.000 7 (58) 8 (67) 1.000 
Age (years) 
median (IQR) 
29 (16) 26 (30) 0.873 71 (25) 65 (15) 0.259 
Smoker n (%) 0 (0) 0 (0) - 3 (25) 6 (50) 0.400 
CRP (mg/l) 
median (IQR) 
- - - 11 (28) 3 (5) 0.101 
RF positive n 
(%) 
- - - 8 (67) 9 (75) 1.000 
Disease 
duration ≥10 
year’s n (%) 
- - - 10 (83) 5 (42) 0.089 
Treatment with 
Methotrexate n 
(%) 
- - - 4 (33) 5 (42) 1.000 
Treatment with 
DMARD’s n 
(%) 
- - - 6 (67) 11 (92) 0.069 
Treatment with 
steroids n (%) 
- - - 4 (33) 3 (25) 1.000 
Treatment with 
NSAID’s n (%) 
- - - 8 (100) 7 (88) 1.000 
 
Data were analysed using Mann-Whitney U for comparison of groups for continuous variables, and 
Fisher’s exact test with a two-tailed p value for the comparison of categorical variables. There were no 
significant differences when groups were compared according to PTPN22 genotype. IQR; interquartile 
range, CRP; C-reactive protein, RF; Rheumatoid factor, DMARD’s; Disease modifying anti-rheumatic 
drugs, NSAID’s; Non-steroidal anti-inflammatory drugs. 
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